Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting (Q34139877)

31 July 2017

title

Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting (English)

1 reference

31 July 2017

0 references

4

William A Denny

1 reference

31 July 2017

author name string

Yvette M Delahoussaye

1

1 reference

31 July 2017

Michael P Hay

2

1 reference

31 July 2017

Frederik B Pruijn

3

1 reference

31 July 2017

J Martin Brown

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

31 July 2017

published in

Biochemical Pharmacology

1 reference

31 July 2017

volume

65

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1807-1815

1 reference

Tirapazamine: a hypoxia-activated topoisomerase II poison.

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Inhibition of DNA replication by tirapazamine.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Therapeutic attack of hypoxic cells of solid tumors: presidential address

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Radioprotection of DNA in isolated nuclei by naturally occurring thiols at intermediate oxygen tension.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Metabolism of tirapazamine by multiple reductases in the nucleus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941974

A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer

28 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900199-0

Direct evidence for bimodal DNA damage induced by tirapazamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900199-0

The new paradigm: Integrating genomic function and nuclear architecture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900199-0

Dihydrorhodamine 123: a fluorescent probe for superoxide generation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900199-0

Bioreductive therapies: an overview of drugs and their mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900199-0

Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical

7 January 2021

1 reference

12 December 2020

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Enzymology of tirapazamine metabolism: a review

1 reference

12 December 2020

The new paradigm: integrating genomic function and nuclear architecture

1 reference

12 December 2020

10.1016/S0006-2952(03)00199-0

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference